Sandoz warns of cheap Chinese imports impacting antibiotic supply
Published on 5/31/2026

AI Summary
Summarized by AI from the source belowSandoz's chief executive expressed concerns that inexpensive imports from China could jeopardize Europe’s antibiotic supply. The company emphasized the need for stronger protections to maintain the continent's medicine capacity. Without these measures, there is a risk of significant supply disruptions in a critical healthcare sector. The potential impact on the pharmaceutical market could affect pricing and availability for consumers in Europe.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News

Pharmaceuticals
Sandoz Collaboration with Henlius Worth Up to $322M for Biosimilars
Aug 17

Earnings
Sandoz (SDZ) Shares Rise 8% After Q2 Biosimilars Beat Earnings
Aug 5

Pharmaceuticals
Novo Nordisk (NVO) Launches Wegovy Pill in UAE, First Outside U.S.
Jun 3

Pharmaceuticals
Revolution Medicines (RVMD) Receives FDA Approval for Daraxonrasib
May 10